Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.42 |
| ▸ | MAPT | P10636 | 6/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.40 |
| ▸ | GPR174 | Q9BXC1 | 3/20 | 0.40 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | CTPS1 | P17812 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 3/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 3/20 | 0.38 |
| ▸ | CSF1R | P07333 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9944808 | 0.87 | KMT2A (0.46) | KMT2AMAPTMAPK1ALDH1A1GPR174 | |
| SCHEMBL9944993 | 0.79 | ALDH1A1 (0.40) | KMT2AMAPTMAPK1ALDH1A1GAA | |
| SCHEMBL9944846 | 0.79 | KMT2A (0.47) | KMT2AMAPTMAPK1ALDH1A1GPR174 | |
| SCHEMBL9945040 | 0.78 | NPC1 (0.40) | KMT2AMAPTALDH1A1GAAHTT | |
| SCHEMBL9945032 | 0.76 | MAPT (0.48) | KMT2AMAPTMAPK1ALDH1A1GAA | |
| SCHEMBL9944769 | 0.76 | MAPT (0.48) | KMT2AMAPTMAPK1ALDH1A1GAA | |
| SCHEMBL9945015 | 0.74 | MAPT (0.42) | KMT2AMAPTMAPK1ALDH1A1GPR174 | |
| SCHEMBL9944989 | 0.73 | ALDH1A1 (0.44) | KMT2AMAPTALDH1A1GAASMN1; SMN2 | |
| SCHEMBL9944806 | 0.72 | ALDH1A1 (0.41) | KMT2AMAPTALDH1A1GAASMN1; SMN2 | |
| SCHEMBL9944969 | 0.72 | ALDH1A1 (0.37) | KMT2AMAPTALDH1A1GAASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8674113-B2 | Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-03-18 | — | — | US | disclosed |
| US-20120149676-A1 | NOVEL COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149676-A1 | NOVEL COMPOUNDS | PTGS1, PTGER1, PTGES | KMT2A 3376/4885MAPT 4336/4885MAPK1 1240/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.